

AVI BIOPHARMA INC
Form 8-K
August 05, 2004

FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **August 5, 2004**

AVI BioPharma, Inc.

(Exact name of registrant as specified in its charter)

Oregon

(State or other jurisdiction of
incorporation or organization)

0-22613

(Commission
File Number)

93 0797222

(IRS Employer
Identification Number)

One S.W. Columbia, Suite 1105

Portland, OR 97258

(Address of principal executive offices)

(503) 227-0554

Registrant's telephone number, including area code

Not Applicable

(Formal name and address, if changed from last report)

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

Exhibits

99.1. Press release dated August 5, 2004 announcing financial results for the three and six months ended June 30, 2004.

Item 9. Regulation FD Disclosure

Information furnished under Item 12.

Item 12. Results of Operations and Financial Condition.

On August 5, 2004, AVI BioPharma, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2004. The press release is attached to this Form 8-K as Exhibit 99.1.

* * *

Note: The information contained in this report on Form 8-K (including Exhibit 99.1) shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on August 5, 2004

AVI BioPharma, Inc.

By: */s/ ALAN P. TIMMINS*
Alan P. Timmins
President and Chief Operating Officer
(Principal Operating Officer)

EXHIBIT INDEX

Exhibit No.	Document Description
99.1	Press release dated August 5, 2004 issued by AVI BioPharma, Inc.